Categories
Prostate cancer

Incidence and survival of castration-resistant prostate cancer patients with visceral metastases: results from the Dutch CAPRI-registry

  • Cornford P, Bellmunt J, Bolla M, Briers E, De Santis M, Gross T, et al. EAU-ESTRO-SIOG guidelines on Prostate Cancer. Part II: treatment of relapsing, metastatic, and castration-resistant Prostate Cancer. Eur Urol. 2017;71:630–42.

    Article 

    Google Scholar
     

  • Eisenberger M, Blumenstein B, Crawford E, Miller G, McLeod D, Loehrer P, et al. Bilateral orchiectomy with or without flutamide for metastatic Prostate Cancer. N. Engl J Med. 1998;339:1036–42.

    Article 

    Google Scholar
     

  • Pezaro C, Omlin A, Lorente D, Nava Rodrigues D, Ferraldeschi R, Bianchini D, et al. Visceral disease in castration-resistant Prostate Cancer. Eur Urol. 2014;65:270–3.

    Article 

    Google Scholar
     

  • Westgeest H, Uyl-de Groot C, van Moorselaar R, de Wit R, van den Bergh A, Coenen J, et al. Differences in trial and real-world populations in the Dutch Castration-resistant Prostate Cancer Registry. Eur Urol Focus. 2018;4:694–701.

    Article 

    Google Scholar
     

  • Whitney C, Howard L, Posadas E, Amling C, Aronson W, Cooperberg M, et al. In men with castration-resistant Prostate Cancer, visceral metastases predict shorter overall survival: what predicts visceral metastases? Results from the SEARCH database. Eur Urol Focus. 2017;3:480–6.

    Article 

    Google Scholar
     

  • Halabi S, Kelly W, Ma H, Zhou H, Solomon N, Fizazi K, et al. Meta-analysis evaluating the impact of site of metastasis on overall survival in men with Castration-Resistant Prostate Cancer. J Clin Oncol. 2016;34:1652–9.

    Article 

    Google Scholar
     

  • van Dodewaard-de Jong J, Verheul H, Bloemendal H, de Klerk J, Carducci M, van den Eertwegh A. New treatment options for patients with metastatic Prostate Cancer: what is the optimal sequence? Clin Genitourin Cancer. 2015;13:271–9.

    Article 

    Google Scholar
     

  • Hussain M, Mateo J, Fizazi K, Saad F, Shore N, Sandhu S, et al. Survival with olaparib in metastatic castration-resistant Prostate Cancer. N. Engl J Med. 2020;383:2345–57.

    Article 

    Google Scholar
     

  • Annala M, Fu S, Bacon J, Sipola J, Iqbal N, Ferrario C, et al. Cabazitaxel versus abiraterone or enzalutamide in poor prognosis metastatic castration-resistant prostate cancer: a multicentre, randomised, open-label, phase II trial. Ann Oncol. 2021;32:896–905.

    Article 

    Google Scholar
     

  • de Wit R, de Bono J, Sternberg C, Fizazi K, Tombal B, Wülfing C, et al. Cabazitaxel versus abiraterone or enzalutamide in metastatic Prostate Cancer. N. Engl J Med. 2019;381:2506–18.

    Article 

    Google Scholar
     

  • Corn PG, Heath EI, Zurita A, Ramesh N, Xiao L, Sei E, et al. Cabazitaxel plus carboplatin for the treatment of men with metastatic castration-resistant prostate cancers: a randomised, open-label, phase 1–2 trial. Lancet Oncol. 2019;20:1432–43.

    Article 

    Google Scholar
     

  • White I, Royston P, Wood A. Multiple imputation using chained equations: issues and guidance for practice. Stat Med. 2010;30:377–99.

  • Hanyok B, Howard L, Amling C, Aronson W, Cooperberg M, Kane C, et al. Is computed tomography a necessary part of a metastatic evaluation for castration-resistant prostate cancer? Results from the shared equal access Regional Cancer Hospital Database. Cancer. 2015;122:222–9.

    Article 

    Google Scholar
     

  • Shenderov E, Velho P, Awan A, Mirkheshti N, Eisenberger M, Pardoll D, et al. Genomic characterization of pulmonary-metastatic prostate cancer: a unique molecular subtype. J Clin Oncol. 2019;37:210–10.

    Article 

    Google Scholar
     

  • Alshalalfa M, Seldon C, Franco I, Vince R, Carmona R, Punnen S, et al. Clinicogenomic characterization of prostate cancer liver metastases. Prostate Cancer and Prostatic Dis. 2022;25:366–9.

    Article 

    Google Scholar
     

  • Halabi S, Lin C, Kelly W, Fizazi K, Moul J, Kaplan E, et al. Updated prognostic model for predicting overall survival in first-line chemotherapy for patients with metastatic castration-resistant Prostate Cancer. J Clin Oncol. 2014;32:671–7.

    Article 

    Google Scholar
     

  • Halabi S, Lin C, Small E, Armstrong A, Kaplan E, Petrylak D, et al. Prognostic model predicting metastatic castration-resistant Prostate Cancer survival in men treated with second-line chemotherapy. JNCI J Natl Cancer Inst. 2013;105:1729–37.

    Article 

    Google Scholar